FDA Analgesic Safety Campaign Launches; Label Warnings Still In Progress
This article was originally published in The Tan Sheet
Executive Summary
FDA launched a public educational campaign Jan. 22 warning consumers about the link between acetaminophen and liver damage, and potential renal and gastrointestinal problems associated with nonsteroidal anti-inflammatory use
You may also be interested in...
FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen
FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen
FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers
FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen